Monthly Vitamin D Supplementation May Lower the Risk of Major CV Events in Older Adults
Vitamin D supplementation may reduce the incidence of major cardiovascular events in older adults, suggests new research.
Daily Dose: Pegozafermin in Patients with NASH
Your daily dose of clinical news you may have missed.
Loneliness Linked to Greater Risk for CVD in Individuals with Diabetes
The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.
ADA Updates Standards of Care, Adding Teplizumab for Delay of T1D, Emphasizing Hepatic Disease Management
The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.
FDA's First Draft Guidance on Clinical Trials with Psychedelic Drugs Now Available for Comment
The FDA's recommendations serve to inform potential research sponsors on development protocols for psychedelics and to solicit comment from industry.
Pegozafermin Shows Early Promise in NASH: Phase 2b ENLIVEN Trial Findings
Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Daily Dose: High-Dose Oral Semaglutide May be Beneficial for T2D Management
FDA Awards De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Decline in Kidney Function in Adults with Type 2 Diabetes and Early-Stage Kidney Disease
KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.
US Overdose Deaths Disproportionately Affect Minority Communities
Black men experienced the highest rate of deaths related to cocaine while American Indian/Native Alaska communities were hit hardest by methamphetamine deaths.
Glycemic Screening in Childhood May Predict Diabetes-Related Complications, According to New Data
ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.
E-Cigarettes: US Sales Nearly Double over 2 Years, Youth Prefer Flavored Disposables
Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.
CDC Endorses GSK, Pfizer RSV Vaccines for Older Adults
The 2 new vaccines are authorized for adults aged 60 years and older and with CDC Director Walensky's final nod, should be available this fall.
HHS: Moving is Good Medicine for Adults aged 65 Years and Older
Less than 15% of US adults in the population aged 65 years and older achieve recommended weekly levels of physical activity and strengthening, according to HHS.
Health Inequities in Persons with Obesity & Type 2 Diabetes Exacerbated During COVID-19 Pandemic
Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.
Studies of Novel, Highly Effective Antiobesity Medications Headline 83rd ADA Scientific Sessions
Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.
Daily Dose: Bempedoic Acid Reduces Risk for MACE in Primary Prevention Population
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes
ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
